MGI Pharma, 0% 2mar2024, USD (7121D) (FIGI BBG000934HG4, WKN A0DG8J)
国内債券, 転換社債, トレース適格, Senior Subordinated Unsecured
国内債券, 転換社債, トレース適格, Senior Subordinated Unsecured
|
MGI Pharma, Inc., a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products for oncology and acute care applications. The company markets Aloxi (palonosetron hydrochloride) Injection, Dacogen (decitabine) for Injection, and Gliadel Wafer (polifeprosan 20 with carmustine ...
MGI Pharma, Inc., a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products for oncology and acute care applications. The company markets Aloxi (palonosetron hydrochloride) Injection, Dacogen (decitabine) for Injection, and Gliadel Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets. The company was formerly known as Molecular Genetics, Inc. and changed its name to MGI Pharma, Inc. in January, 1990. The company was founded in 1979 and is headquartered in Bloomington, Minnesota. It has facilities in Bloomington, Minnesota; Lexington, Massachusetts; and Baltimore, Maryland. As of January 25, 2008, MGI Pharma, Inc. operates as a subsidiary of Eisai Corporation of North America, Inc.
|
|
|
|
|
|
|
|
|
最も包括的なデータベースを探索
1 000 000
債券
80 234
株
175 910
ETF&投資信託
70 000
インデックス
最も効率的な方法でポートフォリオを追跡